Iron deficiency is a frequent co-morbidity in in patients with heart failure with reduced ejection fraction (HFrEF). Current research has shown that intravenous iron replenishment increases exercise tolerance and quality of life in HFrEF patients with iron deficiency. However, case reports have linked the administration of FCM to the development of hypophosphataemia and osteomalacia with fractures. Since Fibroblast Growth Factor 23 (FGF23) is a key regulator of phosphate and Vitamin D metabolism we sought to determine if the administration of FCM increases levels of circulating FGF23 and how this associates with hypophosphatemia induction. METHODS: In this pilot study a total of 23 stable HFrEF patients with a left ventricular ejection fraction < 40% (12 with chronic kidney disease (CKD) as defined by GFR <60ml/min/1.73m 2 (Group HFrEF(þ)CKD) and 11 with GFR > 60 ml/min, Group HFrEF) were identified with iron deficiency (Ferritin <100mg/dl or Ferritin 100-300 mg/dl if TSAT <20%) and received a single dose of 1000 mg FCM. Blood was drawn before, immediately post administration as well as on days 1, 7, 14 and 28. Levels of intact (iFGF23) and c-terminal (cFGF23) FGF23 were determined alongside serum levels of phosphate and 1,25 Vitamin D (calcitriol). RESULTS: Baseline serum phosphate, iFGF23, c-termFGF23, fractional urinary excretion excretion of phosphate were higher in HFrEF(þ)CKD pts compared to HFrEF patients. Administration of FCM resulted in a concordant increase in Ferritin (maximum day 7) and TSAT (maximum immediately post-infusion) in both groups. After administration of FCM, iFGF23 levels rose in both groups reaching their peak already at Day 1 (HfREf(þ)CKD from baseline 214,26188,6 To 384,6 6 91,3 pg/ml (factor 1.8); Group HFrEF from baseline 17,28611.2 to 187,5 6 42,9 pg/ml (Factor 11)). In patients without CKD iFGF23 remained significantly elevated until day 28. In contrast, c-term FGF23 levels decreased towards day 28 in both groups. Serum phosphate decreased significantly only in HFrEF patients without CKD and reached their nadir at Day 14 (-0,34mmol/l compared to baseline) and remained significantly decreased at day 28. Hypophospatemia as defined below 0.8 mmol/L developed in 14 out of 23 pts. Levels of 1,25-Vitamin D significantly decreased in both groups by over 50% with a similar time course as serum phosphate (i.e. partial recovery until day 28 postinfusion). CONCLUSIONS: We show for the first time in a prospective study that the correction of iron deficiency in patients with HFrEF with FCM increases significantly intact FGF23 levels while decreasing c-term FGF23 -thus pointing towards impairement of its degradation. These findings were particularly strong in HFrEF patients without concomitant CKD. The physiological response to increased iFGF23 was clearly detectable: reduction of serum phosphate and increased urinary phosphate excretion. Our study underlines the need to assess long-term safety of FCM administration in HFrEF patients since the observed derangements in FGF23-phosphate metabolism might impair myocardial function and induce osteomalacia particurlay with repetitive dosing.
INTRODUCTION AND AIMS:
Iron deficiency is a frequent co-morbidity in in patients with heart failure with reduced ejection fraction (HFrEF) . Current research has shown that intravenous iron replenishment increases exercise tolerance and quality of life in HFrEF patients with iron deficiency. However, case reports have linked the administration of FCM to the development of hypophosphataemia and osteomalacia with fractures. Since Fibroblast Growth Factor 23 (FGF23) is a key regulator of phosphate and Vitamin D metabolism we sought to determine if the administration of FCM increases levels of circulating FGF23 and how this associates with hypophosphatemia induction. METHODS: In this pilot study a total of 23 stable HFrEF patients with a left ventricular ejection fraction < 40% (12 with chronic kidney disease (CKD) as defined by GFR <60ml/min/1.73m 2 (Group HFrEF(þ)CKD) and 11 with GFR > 60 ml/min, Group HFrEF) were identified with iron deficiency (Ferritin <100mg/dl or Ferritin 100-300 mg/dl if TSAT <20%) and received a single dose of 1000 mg FCM. Blood was drawn before, immediately post administration as well as on days 1, 7, 14 and 28. Levels of intact (iFGF23) and c-terminal (cFGF23) FGF23 were determined alongside serum levels of phosphate and 1,25 Vitamin D (calcitriol). RESULTS: Baseline serum phosphate, iFGF23, c-termFGF23, fractional urinary excretion excretion of phosphate were higher in HFrEF(þ)CKD pts compared to HFrEF patients. Administration of FCM resulted in a concordant increase in Ferritin (maximum day 7) and TSAT (maximum immediately post-infusion) in both groups. After administration of FCM, iFGF23 levels rose in both groups reaching their peak already at Day 1 (HfREf(þ)CKD from baseline 214,26188,6 To 384,6 6 91,3 pg/ml (factor 1.8); Group HFrEF from baseline 17,28611.2 to 187,5 6 42,9 pg/ml (Factor 11)). In patients without CKD iFGF23 remained significantly elevated until day 28. In contrast, c-term FGF23 levels decreased towards day 28 in both groups. Serum phosphate decreased significantly only in HFrEF patients without CKD and reached their nadir at Day 14 (-0,34mmol/l compared to baseline) and remained significantly decreased at day 28. Hypophospatemia as defined below 0.8 mmol/L developed in 14 out of 23 pts. Levels of 1,25-Vitamin D significantly decreased in both groups by over 50% with a similar time course as serum phosphate (i.e. partial recovery until day 28 postinfusion). CONCLUSIONS: We show for the first time in a prospective study that the correction of iron deficiency in patients with HFrEF with FCM increases significantly intact FGF23 levels while decreasing c-term FGF23 -thus pointing towards impairement of its degradation. These findings were particularly strong in HFrEF patients without concomitant CKD. The physiological response to increased iFGF23 was clearly detectable: reduction of serum phosphate and increased urinary phosphate excretion. Our study underlines the need to assess long-term safety of FCM administration in HFrEF patients since the observed derangements in FGF23-phosphate metabolism might impair myocardial function and induce osteomalacia particurlay with repetitive dosing. between serum markers of the disease. Previous studies attempted to address this issue by assessing outcomes in mutually exclusive BMD phenotypes based on patient's calcium, phosphorus and PTH serum concentrations. However, this evidence is limited by relatively short follow up and insufficient statistical power for important clusters. Additionally, generizability was questionable due to exclusive use of North American patients' data. We aimed at evaluating survival and hospitalization risk associated with mutually exclusive BMD phenotypes in an international sample of hemodialysis patients. METHODS: We conducted a historical cohort study by enrolling all patients registeredin EUCLID V R network on 07/01/2011 (28 EMEA and South American countries), with at least 180 days of Renal Replacement Therapy before the index date (run-in) and at least 30 days of survival. We classified patients in mutually exclusive phenotipes based on 6-month averaged P, Ca and PTH serum concentrations classes (L: Low; N: Normal; H: High) defined by established normality cutoffs. We excluded patients with incomplete MBD assessment and those belonging to very small phenotype clusters (n<100). Patients' outcomes have been observed for up to 5 years. Survival analysis (mortality and composite of mortality or hospitalization) was adjusted for age, sex, ethnicity, smoke, RRT vintage, BMI, etiology, albumin, hemoglobin, ferritin, glucose, diabetes, cardiac dysrhythmia, cancer, liver disease, COPD, Peripheral vascular disease, GI bleeding, and cardiovascular comorbidities. RESULTS: There were 35763 patients satisfying inclusion/exclusion criteria and had full MBD assessment; 41 patients belonged to classes with less than 100 subjects (PTH/ Ca/P: HLL, HNL, LHL, NHL). Mean age was 61.8 (SD: 15.7), and the average time on dialysis was 5.3 years (SD: 4.9); 26.9% of patients had diabetes and 60.5% hypertension. There were 15773 deaths (128.9 deaths/1000 person-years). Global mortality risk was reported in figure 1. Adjusted association between MBD phenotypes, mortality and hospitalization is reported in figure 2.
CONCLUSIONS:
We highlighted MBD phenotypes associated with substantial risk which should be addressed more aggressively. Data show that mortality and hospitalization risk is best explained by complex biomarkers configurations and cannot be directly inferred by the status of any single MBD marker alone. 
